Furthermore, since GLP-1 signaling was suggested as a common pathophysiological mechanism in both Alzheimer’s disease and T2DM, GLP-1 agonists may prevent cognitive decline (68). This evidence concerns the gene GCG and early-onset autosomal dominant Alzheimer disease.